VPS35 Antibody, Clone 10A8: ATTO 488

Vacuolar Protein Sorter 35 (VPS35) is a core component of the retromer complex, a critical intracellular trafficking system responsible for the endosome-to-Golgi retrieval of membrane proteins. This pathway is essential for maintaining protein homeostasis, synaptic function, and neuronal survival. Mutations in VPS35—most notably the D620N variant—have been directly linked to familial and sporadic forms of Parkinson’s disease (PD) . These mutations impair retromer function, leading to disrupted recycling of key neuronal receptors and transporters. Dysfunctional VPS35 also contributes to mitochondrial fragmentation, oxidative stress, and impaired autophagy—cellular processes that are central to the pathogenesis of neurodegenerative diseases. Beyond Parkinson’s, VPS35 dysfunction has been implicated in Alzheimer’s disease and other proteinopathies, where it affects the trafficking of amyloid precursor protein (APP) and tau. Its role in regulating endosomal sorting and mitochondrial dynamics positions VPS35 as a critical node in the cellular pathways that maintain neuronal integrity. As a result, VPS35 is emerging as a promising therapeutic target in neurodegenerative disease research. Restoring or enhancing retromer function may offer novel strategies to counteract protein misfolding, synaptic loss, and neuroinflammation.

VPS35, VPS35 Retromer Complex Component, Vacuolar Protein Sorting-Associated Protein 35, Vacuolar Protein Sorting 35 Homolog, Vesicle Protein Sorting 35, MEM3, PARK17, FLJ10752, HVPS35, Maternal-Embryonic 3, TCCCTA00141

Cell Signaling | Neuroscience |Neurodegeneration | Parkinson's Disease | Membrane Trafficking Proteins | Golgi Proteins | Protein Trafficking | Alzheimer's Disease

A 1:1000 dilution of SMC-605 was sufficient for detection of VPS35 in 10 µg of SH-SY5Y by ECL immunoblot analysis using Goat Anti-Mouse IgG:HRP as the secondary antibody.

WB (1:1000) ; ICC/IF (1:200) ; IP (1:200) ; IHC (1:100) ; optimal dilutions for assays should be determined by the user.; optimal dilutions for assays should be determined by the user.

1. Vilarino-Guell, C. et al. (2011) Am J Hum Genet 89:162–167 2. Zimprich, A. et al. (2011) Am J Hum Genet 89:168–175 3. Rahman, A.A., Morrison, B.E. (2019) Neurosci 401:1-10.

1. Vilarino-Guell, C. et al. (2011) Am J Hum Genet 89:162–167 2. Zimprich, A. et al. (2011) Am J Hum Genet 89:168–175 3. Rahman, A.A., Morrison, B.E. (2019) Neurosci 401:1-10.